SG
Sweta Girgenrath
Vice President, Therapeutic Research and External Innovation Lead
Entrada TherapeuticsTherapeutic Areas
Entrada Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| ENTR-601-44 | Duchenne Muscular Dystrophy (Exon 44 skipping) | Phase 1/2b |
| ENTR-701 | Myotonic Dystrophy Type 1 | Phase 1 |
| ENTR-601-51 | Duchenne Muscular Dystrophy (Exon 51 skipping) | Preclinical |
| ENTR-601-50 | Duchenne Muscular Dystrophy (Exon 50 skipping) | Preclinical |
Leadership Team at Entrada Therapeutics
MS
Michael St. Andre
Principal Scientist
HL
Haoming Liu
Principal Scientist
DP
Dehua Pei
Scientific Co-Founder